Home  |  Site Map  |  Contact Us  |  
Search

 

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. XenoPort is currently commercializing HORIZANT® (gabapentin enacarbil) Extended-Release Tablets in the United States and developing its novel fumaric acid ester product candidate, XP23829, as a potential treatment for patients with moderate-to-severe chronic plaque-type psoriasis and/or relapsing forms of Multiple Sclerosis. REGNITE® (gabapentin enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas Pharma Inc. XenoPort recently granted exclusive world-wide rights for the development and commercialization of its clinical-stage oral product candidate, arbaclofen placarbil, to Reckitt Benckiser Pharmaceuticals, Inc. for all indications. XenoPort's pipeline of product candidates also includes a potential treatment for patients with Parkinson's disease.

For more information, please click here


For more information, please click here

Thu, 29 Jan 2015
XenoPort Announces Pricing of $100 Million 2.50% Convertible Senior Notes due 2022

Wed, 28 Jan 2015
XenoPort Announces Proposed Offering of $100 Million Convertible Senior Notes due 2022

 

2014 Credit Suisse Healthcare Conference
November 12, 2014 at 8:30 AM PT

Q3 2014 XenoPort, Inc. Earnings Conference Call
November 4, 2014 at 5:00 PM ET

XenoPort is focused on development of product candidates for the potential treatment of central nervous system (CNS) disorders, including spasticity, Parkinsonís disease and relapsing-remitting multiple sclerosis.

Explore the XenoPort Pipeline >